Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) shares saw unusually-strong trading volume on Thursday . Approximately 286,014 shares were traded during trading, an increase of 7% from the previous session’s volume of 266,853 shares.The stock last traded at $2.94 and had previously closed at $3.05.

Separately, Maxim Group reaffirmed a “buy” rating and set a $17.00 price target on shares of Adamis Pharmaceuticals Corp. in a research note on Monday, June 6th.

The stock’s market cap is $46.22 million. The stock’s 50-day moving average is $3.95 and its 200 day moving average is $5.65.

In other Adamis Pharmaceuticals Corp. news, SVP David J. Marguglio sold 4,000 shares of the firm’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $8.08, for a total transaction of $32,320.00. Following the transaction, the senior vice president now owns 102,227 shares in the company, valued at approximately $825,994.16. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP David J. Marguglio sold 4,860 shares of the firm’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $10.00, for a total value of $48,600.00. Following the transaction, the senior vice president now owns 106,227 shares in the company, valued at approximately $1,062,270. The disclosure for this sale can be found here.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.